Medistim

Regulatory Filings • Sep 23, 2015

Medistim introduces its new specialized product for vascular surgery

Medistim introduces its new specialized product for vascular surgery

(Oslo, 23 September 2015) Medistim ASA (OSE: MEDI)

is a medtech company that develops and sells

equipment for intraoperative ultrasound based

surgical guidance and quality assurance in

connection with the intervention of condensed

arteries. The company announces that it introduces

its new solution within vascular surgery during the

annual Congress of the European Society of Vascular

Surgery (ESVS).

ESVS Congress gathers vascular surgeons from across

Europe and is this year held in Porto, Portugal from

23rd to 25th of September. At this congress Medistim

will present its new system MiraQ Vascular together

with new custom made flow probes that are

specifically designed to meet the needs of

intraoperative ultrasound guidance and quality

assurance within vascular surgery. The system

represents a new product line that is originated

from the MiraQ platform. The first product line on

this platform was MiraQ Cardiac, launched in

October 2014. In addition to general improvements,

the MiraQ Vascular product comes with specialized

control panel, an application that is customized

with a user interface adapted to the vascular

surgeons needs, and new probes tailored for the

vascular application areas.

The launch of the new vascular solution is in line

with Medistims strategy, as stated earlier by the

company. The global vascular market represents a

significant opportunity for Medistim and is

estimated to represent approximately 600,000

procedures annually. In comparison, cardiac bypass

surgery, a segment where Medistim has its strongest

position with a global market penetration of 20-25%,

represent 700,000 procedures annually. Medistim

estimate that the vascular market has an annual

potential of NOK 1 billion. The company is well

positioned in the vascular market in the Nordic

countries and in Germany, but has so far only a

modest coverage in the vascular segment in other

countries.

There are many types of applications within vascular

surgery. Key target segments for Medistim will be

peripheral bypass surgery and carotid

endarterectomy, where the global number of

procedures performed per year is 200,000 and 225,000

respectively. Peripheral bypass surgery is performed

primarily on the major arteries in the legs. Carotid

endarterectomy is a procedure where blockages in the

neck arteries surgically are removed to ensure fresh

blood flow to the brain. The new MiraQ Vascular

product support both type of interventions using

ultrasound imaging and blood flow measurements to

guide the surgeon during the procedure and to

quality assure clinical outcome.

"We are very pleased to introduce an integrated and

customized solution for vascular surgery" says Kari

E. Krogstad, CEO of Medistim ASA. "This is in

accordance with our strategy and we will now work

focused towards this customer group that represent a

huge revenue potential for Medistim".

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

E-mail: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

E-mail: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track

record of profitable growth over the past >10

years. The company is a pioneer within its segment,

and continues to invest in new product development.

Medistim has wholly owned subsidiaries with sales

organizations in the USA, Germany, UK, Denmark and

Norway, in addition to about 50 distributors in

Europe, Asia, Middle East, Africa and South

America.

For more information, visit the Medistim home page:

www.medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).